Traditional and New Composite Endpoints in Heart Failure Clinical Trials: Facilitating Comprehensive Efficacy Assessments and Improving Trial Efficiency
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Composite endpoints are commonly used as the primary measure of efficacy in heart failure clinical trials to assess the overall treatment effect and to increase the efficiency of trials. Clinical trials still must enrol large numbers of patients to accrue a sufficient number of outcome events and have adequate power to draw conclusions about the efficacy and safety of new treatments for heart failure. Additionally, the societal and health system perspectives on heart failure have raised interest in ascertaining the effects of therapy on outcomes such as repeat hospitalization and the patient’s burden of disease. Thus, novel methods for using composite endpoints in clinical trials (e.g. clinical status composite endpoints, recurrent event analyses) are being applied in current and planned trials. Endpoints that measure functional status or reflect the patient experience are important but used cautiously because heart failure treatments may improve function yet have adverse effects on mortality. This paper discusses the use of traditional and new composite endpoints, identifies qualities of robust composites, and outlines opportunities for future research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Self-citationAmiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart Failure
Bardy, G. H., Lee, K. L., Mark, D. B., Poole, J. E., Packer, D. L., Boineau, R., Domanski, M., Troutman, C., Anderson, J., Johnson, G., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043399 · Cited by 6,552
Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events
Moss, A. J., Hall, W. J., Cannom, D. S., Klein, H., Brown, M. W., Daubert, J. P., Estes, N. A. M., Foster, E., Greenberg, H., Higgins, S. L., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906431 · Cited by 3,157
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Cohn, J. N., Johnson, G., Ziesche, S., Cobb, F., Francis, G., Tristani, F., Smith, R., Dunkman, W. B., Loeb, H., Wong, M., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250502 · Cited by 2,833
Spironolactone for heart failure with preserved ejection fraction
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313731 · Cited by 2,809
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
Swedberg, K., Komajda, M., Böhm, M., Borer, J. S., Ford, I., Dubost-Brama, A., Lerebours, G., & Tavazzi, L. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61198-1 · Cited by 2,563 · cited 2×
“For example, in the Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial (SHIFT) study, the primary endpoint was a composite of cardiovascular death or hospital admission for worsening heart failure.(14) Ivabradine reduced the risk of the primary”
BackgroundMethodSelf-citationCardiac-Resynchronization Therapy for Mild-to-Moderate Heart Failure
Tang, A. S. L., Wells, G. A., Talajic, M., Arnold, M. O., Sheldon, R., Connolly, S., Hohnloser, S. H., Nichol, G., Birnie, D. H., Sapp, J. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1009540 · Cited by 1,859
Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure
Taylor, A. L., Ziesche, S., Yancy, C., Carson, P., D'Agostino, R., Ferdinand, K., Taylor, M., Adams, K., Sabolinski, M., Worcel, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042934 · Cited by 1,773
Abraham, W. T., Adamson, P. B., Bourge, R. C., Aaron, M. F., Costanzo, M. R., Stevenson, L. W., Strickland, W., Neelagaru, S., Raval, N., Krueger, S., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60101-3 · Cited by 1,744
Cited by
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
Self-citation2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Self-citationAuthors/Task Force Members:, McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2333 · Cited by 2,171
Self-citationJCS/JACR 2021 Guideline on Rehabilitation in Patients With Cardiovascular Disease
Makita, S., Yasu, T., Akashi, Y. J., Adachi, H., Izawa, H., Ishihara, S., Iso, Y., Ohuchi, H., Omiya, K., Ohya, Y., et al. (2022) · Circulation Journal · doi:10.1253/circj.cj-22-0234 · Cited by 287
Cardiac Resynchronization Therapy With Wireless Left Ventricular Endocardial Pacing
Reddy, V. Y., Miller, M. A., Neuzil, P., Søgaard, P., Butter, C., Seifert, M., Delnoy, P. P., van Erven, L., Schalji, M., Boersma, L. V. A., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.02.059 · Cited by 214
Schwartz, G. G., Fayyad, R., Szarek, M., DeMicco, D., & Olsson, A. G. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317708677 · Cited by 44
“There is increasing recognition that analysis of recurrent events is an approach that may better estimate the total impact of cardiovascular disease on the patient, and provide a means to enhance the efficiency of clinical trials.(4) Accordingly, we conducted a post-hoc analysis of the effect of atorvastatin on first…”
BackgroundDewan, P., Solomon, S. D., Jhund, P. S., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., DeMets, D. L., Sabatine, M. S., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1867 · Cited by 41
Self-citationClinical Trial Design, Endpoints, and Regulatory Requirements
Rosano, G. M. C. (2016) · Handbook of Experimental Pharmacology · doi:10.1007/164_2016_75 · Cited by 7
Self-citation
Metadata
- Authors
- Anker, S. D., Schroeder, S., Atar, D., Bax, J. J., Ceconi, C., Cowie, M. R., Crisp, A., Dominjon, F., Ford, I., Ghofrani, H.-A., Gropper, S., Hindricks, G., Hlatky, M. A., Holcomb, R., Honarpour, N., Jukema, J. W., Kim, A. M., Kunz, M., Lefkowitz, M., Le Floch, C., Landmesser, U., McDonagh, T. A., McMurray, J. J., Merkely, B., Packer, M., Prasad, K., Revkin, J., Rosano, G. M. C., Somaratne, R., Stough, W. G., Voors, A. A., & Ruschitzka, F.
- Venue
- European Journal of Heart Failure
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-04-12
- Volume
- 18
- Issue
- 5
- Pages
- 482-489
- ISSN
- 1388-9842 (ISSN-L)
- 1879-0844
- OpenAlex
- W2339635573
- Cited by
- 97
- References
- 20
- FWCI
- 11.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.